This paper investigated the effects of plasma volume and extraction buffer volume on the yield of cell-free (cfDNA) and on determination of fractional abundance of mutations.
Optimized (pre) Analytic Conditions and Workflow for ddPCR Analysis of cfDNA from Patients Suspected of Lung Carcinoma.
de Kock R, Deiman B, Kraaijvanger R, Scharnhorst V
Purpose
Conclusion
The isolation efficiency was highest when 3 mL of plasma was used along with 35 µL of extraction buffer (Method A), but the concentration of cfDNA in the extract was highest when 2 x 4 mL of plasma with 70 µL of extraction buffer was used (Method E). A comparison of Methods A and E revealed more copies of wildtype (WT) DNA using Method E but there were also more copies of the KRAS proto-oncogene (KRAS) and epidermal growth factor receptor (EGFR) mutant DNA, such that the fractional abundance of the mutant DNA was comparable between the two methods. Further analysis of extraction Method E revealed that >1500 copies of WT KRAS were detected in 76% of specimens and for those yielding <1500 copies, a second run allowed for detection of 1500 copies WT KRAS. The authors calculated that between 1500 and 5000 WT copies of KRAS and 1500-7000 copies of WT L861Q EGFR are necessary for a limit of detection of at least 0.20% and reliable determination of fractional abundance. Importantly, EGFR multiplex and simplex assays resulted in comparable mutant concentration and fractional abundance.ional abundance.
Studies (1)
Purpose
The purpose of this study was to investigate the effects of plasma volume and extraction buffer volume on the yield of cfDNA and on determination of fractional abundance of mutations. Blood was collected into two EDTA and two PAXgene Blood ccfDNA tubes from each of 68 patients suspected to have lung carcinoma. Plasma was obtained from EDTA blood by centrifugation at 820 x g for 10 min within 4 h of collection. Plasma was obtained from PAXgene blood by centrifugation at 1900 x g for 15min within 5 days of collection. Plasma was aliquoted and centrifuged at 16,100 x g for 10 min and the resultant supernatant stored in cryotubes at -80˚C. cfDNA was isolated from plasma pools (20 patients/pool) using the Qiagen Circulating Nucleic acid kit using different 3 mL of plasma and 35 (Method A) or 50 µL (Method B) of extraction buffer, 4 mL of plasma and 45 µL extraction buffer (Method C), 2 x 3 mL aliquots of plasma (two filters) and 70 µL extraction buffer (Method D), or 2 x 4 mL of plasma (two filters) and 70 (Method E) or 90 µL (Method F) of extraction buffer. cfDNA was stored at -80˚C. cfDNA was quantified by ddPCR using the KRAS G12/G13 Screening Multiplex Kit. Mutational screens were further investigated by ddPCR amplification of three EGFR TKI sensitive mutations.
Summary of Findings
The isolation efficiency was highest when 3 mL of plasma was used along with 35 µL of extraction buffer (Method A) but the efficiency was only significantly different from that when 3 mL plasma was used along with 50 µL extraction buffer (Method B, 3048 copies/mL plasma versus 2166 copies/mL plasma, P<0.01). The concentration of cfDNA in the extract was higher when more than 4 mL of plasma was used (Methods C-F) than when 3 mL of plasma was used (Methods A or B), regardless of extraction buffer volume (P<0.01) and, in the case of 2 x 4 mL of plasma with 70 µL extraction buffer (Method E), the concentration was higher than all other methods (P≤0.002). A comparison of Methods A and E revealed more copies of WT DNA using Method E, but there were also more copies of the KRAS and EGFR mutant DNA such that the fractional abundance of the mutant DNA was comparable between Methods A and E (0.32 versus 0.33 for KRAS and 0.56 versus 0.50 for EGFR). Further analysis of extraction Method E revealed that >1500 copies of WT KRAS were detected in 76% of specimens and, for those yielding <1500 copies, a second run allowed for detection of 1500 copies of WT KRAS. The authors calculated that between 1500 and 5000 WT copies of KRAS and 1500-7000 copies WT L861Q WT EGFR are necessary for a limit of detection of at least 0.20% and reliable determination of fractional abundance. Importantly, EGFR multiplex and simplex assays resulted in comparable mutant concentration and fractional abundance.
Biospecimens
FluidPlasmaPreservation Types
FrozenDiagnoses
NeoplasticCarcinomaPlatforms
DNADigital PCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Aliquots and Components Aliquot size/volume 2 x 3 mL plasma2 x 4 mL plasma3 mL plasma4 mL plasmaAnalyte Extraction and Purification Analyte isolation method 2 x 3 mL plasma (two filters) and 70 µL extraction buffer (Method D)2 x 4 mL plasma (two filters) and 70 µL extraction buffer(Method E)2 x 4 mL plasma (two filters) and 90 µL extraction buffer(Method F)3 mL plasma and 35 µL extraction buffer (Method A)3 mL plasma and 50 µL extraction buffer (Method B)4 mL plasma and 45 µL extraction buffer (Method C)